×




Exubera and NICE Net Present Value (NPV) / MBA Resources

Introduction to Net Present Value (NPV) - What is Net Present Value (NPV) ? How it impacts financial decisions regarding project management?

NPV solution for Exubera and NICE case study


At Oak Spring University, we provide corporate level professional Net Present Value (NPV) case study solution. Exubera and NICE case study is a Harvard Business School (HBR) case study written by Stefanos Zenios, Robert Chess, Lyn Denend. The Exubera and NICE (referred as “Payers Exubera” from here on) case study provides evaluation & decision scenario in field of Leadership & Managing People. It also touches upon business topics such as - Value proposition, Health, Personnel policies, Research & development.

The net present value (NPV) of an investment proposal is the present value of the proposal’s net cash flows less the proposal’s initial cash outflow. If a project’s NPV is greater than or equal to zero, the project should be accepted.

NPV = Present Value of Future Cash Flows LESS Project’s Initial Investment






Case Description of Exubera and NICE Case Study


Historically, the biggest obstacle that healthcare innovators, such as pharmaceutical and medical device manufacturers, needed to overcome on their way to market was securing approval by the U.S. Food & Drug Administration (FDA) or other international regulatory authorities. However, in the last decade, a new (sometimes even more challenging) hurdle had to be cleared: insurance coverage and reimbursement. Payers--either public payers, such as Medicare in the U.S. and the National Health Services (NHS) in the U.K., or private commercial payers, such as Blue Cross/Blue Shield and UnitedHealth Grou--could deny coverage for a technology that had received regulatory approval if they determined that the supporting evidence did not adequately demonstrate that the technology was superior to existing treatment alternatives that were already being reimbursed. This had the potential to create a potentially adversarial relationship between payers and innovators in cases where they had conflicting interpretations of the evidence regarding the cost, benefits, and risks of new technologies. The challenges to innovators in managing this conflict are illustrated in this case study by an example: the 2006 decision by the U.K.'s NHS to deny coverage for Exubera, a new form of inhaled insulin.


Case Authors : Stefanos Zenios, Robert Chess, Lyn Denend

Topic : Leadership & Managing People

Related Areas : Health, Personnel policies, Research & development




Calculating Net Present Value (NPV) at 6% for Exubera and NICE Case Study


Years              Cash Flow     Net Cash Flow     Cumulative    
Cash Flow
Discount Rate
@ 6 %
Discounted
Cash Flows
Year 0 (10027005) -10027005 - -
Year 1 3448011 -6578994 3448011 0.9434 3252841
Year 2 3970912 -2608082 7418923 0.89 3534098
Year 3 3954291 1346209 11373214 0.8396 3320099
Year 4 3222128 4568337 14595342 0.7921 2552227
TOTAL 14595342 12659264




The Net Present Value at 6% discount rate is 2632259

In isolation the NPV number doesn't mean much but put in right context then it is one of the best method to evaluate project returns. In this article we will cover -

Different methods of capital budgeting


What is NPV & Formula of NPV,
How it is calculated,
How to use NPV number for project evaluation, and
Scenario Planning given risks and management priorities.




Capital Budgeting Approaches

Methods of Capital Budgeting


There are four types of capital budgeting techniques that are widely used in the corporate world –

1. Payback Period
2. Profitability Index
3. Net Present Value
4. Internal Rate of Return

Apart from the Payback period method which is an additive method, rest of the methods are based on Discounted Cash Flow technique. Even though cash flow can be calculated based on the nature of the project, for the simplicity of the article we are assuming that all the expected cash flows are realized at the end of the year.

Discounted Cash Flow approaches provide a more objective basis for evaluating and selecting investment projects. They take into consideration both –

1. Timing of the expected cash flows – stockholders of Payers Exubera have higher preference for cash returns over 4-5 years rather than 10-15 years given the nature of the volatility in the industry.
2. Magnitude of both incoming and outgoing cash flows – Projects can be capital intensive, time intensive, or both. Payers Exubera shareholders have preference for diversified projects investment rather than prospective high income from a single capital intensive project.






Formula and Steps to Calculate Net Present Value (NPV) of Exubera and NICE

NPV = Net Cash In Flowt1 / (1+r)t1 + Net Cash In Flowt2 / (1+r)t2 + … Net Cash In Flowtn / (1+r)tn
Less Net Cash Out Flowt0 / (1+r)t0

Where t = time period, in this case year 1, year 2 and so on.
r = discount rate or return that could be earned using other safe proposition such as fixed deposit or treasury bond rate. Net Cash In Flow – What the firm will get each year.
Net Cash Out Flow – What the firm needs to invest initially in the project.

Step 1 – Understand the nature of the project and calculate cash flow for each year.
Step 2 – Discount those cash flow based on the discount rate.
Step 3 – Add all the discounted cash flow.
Step 4 – Selection of the project

Why Leadership & Managing People Managers need to know Financial Tools such as Net Present Value (NPV)?

In our daily workplace we often come across people and colleagues who are just focused on their core competency and targets they have to deliver. For example marketing managers at Payers Exubera often design programs whose objective is to drive brand awareness and customer reach. But how that 30 point increase in brand awareness or 10 point increase in customer touch points will result into shareholders’ value is not specified.

To overcome such scenarios managers at Payers Exubera needs to not only know the financial aspect of project management but also needs to have tools to integrate them into part of the project development and monitoring plan.

Calculating Net Present Value (NPV) at 15%

After working through various assumptions we reached a conclusion that risk is far higher than 6%. In a reasonably stable industry with weak competition - 15% discount rate can be a good benchmark.



Years              Cash Flow     Net Cash Flow     Cumulative    
Cash Flow
Discount Rate
@ 15 %
Discounted
Cash Flows
Year 0 (10027005) -10027005 - -
Year 1 3448011 -6578994 3448011 0.8696 2998270
Year 2 3970912 -2608082 7418923 0.7561 3002580
Year 3 3954291 1346209 11373214 0.6575 2600011
Year 4 3222128 4568337 14595342 0.5718 1842262
TOTAL 10443123


The Net NPV after 4 years is 416118

(10443123 - 10027005 )








Calculating Net Present Value (NPV) at 20%


If the risk component is high in the industry then we should go for a higher hurdle rate / discount rate of 20%.

Years              Cash Flow     Net Cash Flow     Cumulative    
Cash Flow
Discount Rate
@ 20 %
Discounted
Cash Flows
Year 0 (10027005) -10027005 - -
Year 1 3448011 -6578994 3448011 0.8333 2873343
Year 2 3970912 -2608082 7418923 0.6944 2757578
Year 3 3954291 1346209 11373214 0.5787 2288363
Year 4 3222128 4568337 14595342 0.4823 1553881
TOTAL 9473164


The Net NPV after 4 years is -553841

At 20% discount rate the NPV is negative (9473164 - 10027005 ) so ideally we can't select the project if macro and micro factors don't allow financial managers of Payers Exubera to discount cash flow at lower discount rates such as 15%.





Acceptance Criteria of a Project based on NPV

Simplest Approach – If the investment project of Payers Exubera has a NPV value higher than Zero then finance managers at Payers Exubera can ACCEPT the project, otherwise they can reject the project. This means that project will deliver higher returns over the period of time than any alternate investment strategy.

In theory if the required rate of return or discount rate is chosen correctly by finance managers at Payers Exubera, then the stock price of the Payers Exubera should change by same amount of the NPV. In real world we know that share price also reflects various other factors that can be related to both macro and micro environment.

In the same vein – accepting the project with zero NPV should result in stagnant share price. Finance managers use discount rates as a measure of risk components in the project execution process.

Sensitivity Analysis

Project selection is often a far more complex decision than just choosing it based on the NPV number. Finance managers at Payers Exubera should conduct a sensitivity analysis to better understand not only the inherent risk of the projects but also how those risks can be either factored in or mitigated during the project execution. Sensitivity analysis helps in –

What are the uncertainties surrounding the project Initial Cash Outlay (ICO’s). ICO’s often have several different components such as land, machinery, building, and other equipment.

What can impact the cash flow of the project.

Understanding of risks involved in the project.

What will be a multi year spillover effect of various taxation regulations.

What are the key aspects of the projects that need to be monitored, refined, and retuned for continuous delivery of projected cash flows.

Some of the assumptions while using the Discounted Cash Flow Methods –

Projects are assumed to be Mutually Exclusive – This is seldom the came in modern day giant organizations where projects are often inter-related and rejecting a project solely based on NPV can result in sunk cost from a related project.

Independent projects have independent cash flows – As explained in the marketing project – though the project may look independent but in reality it is not as the brand awareness project can be closely associated with the spending on sales promotions and product specific advertising.






Negotiation Strategy of Exubera and NICE

References & Further Readings

Stefanos Zenios, Robert Chess, Lyn Denend (2018), "Exubera and NICE Harvard Business Review Case Study. Published by HBR Publications.


Axway SWOT Analysis / TOWS Matrix

Technology , Software & Programming


Sam-A Pharm SWOT Analysis / TOWS Matrix

Healthcare , Biotechnology & Drugs


Engage:BDR SWOT Analysis / TOWS Matrix

Technology , Computer Services


Sachem Capital SWOT Analysis / TOWS Matrix

Financial , Consumer Financial Services


China Wah Yan Healthcare SWOT Analysis / TOWS Matrix

Healthcare , Medical Equipment & Supplies


Aida Engineering SWOT Analysis / TOWS Matrix

Capital Goods , Misc. Capital Goods


Infrastructure India SWOT Analysis / TOWS Matrix

Financial , Misc. Financial Services


UltraTech Cement SWOT Analysis / TOWS Matrix

Capital Goods , Construction - Raw Materials